Search research articles
Contact Us
Filters
Showing results (51-60 of 106) with videos related to
Page
of 11
Sort By:
Journal of Clinical Medicine
|
March 11, 2023
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Maxime Borgeaud, Floryane Kim, Alex Friedlaender, et al.
Cancer Treatment Reviews
|
February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Alex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Frontiers in Oncology
|
March 3, 2020
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender, Thierry Nouspikel, Yann Christinat, et al.
Cancer Treatment Reviews
|
February 26, 2022
Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350]
Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
Cancer Treatment Reviews
|
April 2, 2021
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, et al.
Clinical Lung Cancer
|
June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
Alex Friedlaender, Stephen V Liu, Antonio Passaro, et al.
Cancer Investigation
|
August 19, 2021
Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with Chemotherapy
Giuseppe Luigi Banna, Ornella Cantale, Alex Friedlaender, et al.
International Journal of Molecular Sciences
|
July 29, 2023
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Emma Boydell, Jose L Sandoval, Olivier Michielin, et al.
Cancer Treatment Reviews
|
January 30, 2022
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
International Journal of Molecular Sciences
|
September 4, 2020
Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Alex Friedlaender, Alfredo Addeo, Alessandro Russo, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 106) with videos related to
Sort By:
Page
of 11
Journal of Clinical Medicine
|
March 11, 2023
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Maxime Borgeaud, Floryane Kim, Alex Friedlaender, et al.
Cancer Treatment Reviews
|
February 17, 2020
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Alex Friedlaender, Alexander Drilon, Glen J Weiss, et al.
Frontiers in Oncology
|
March 3, 2020
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender, Thierry Nouspikel, Yann Christinat, et al.
Cancer Treatment Reviews
|
February 26, 2022
Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350]
Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
Cancer Treatment Reviews
|
April 2, 2021
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, et al.
Clinical Lung Cancer
|
June 6, 2020
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
Alex Friedlaender, Stephen V Liu, Antonio Passaro, et al.
Cancer Investigation
|
August 19, 2021
Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with Chemotherapy
Giuseppe Luigi Banna, Ornella Cantale, Alex Friedlaender, et al.
International Journal of Molecular Sciences
|
July 29, 2023
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Emma Boydell, Jose L Sandoval, Olivier Michielin, et al.
Cancer Treatment Reviews
|
January 30, 2022
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, et al.
International Journal of Molecular Sciences
|
September 4, 2020
Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Alex Friedlaender, Alfredo Addeo, Alessandro Russo, et al.
Page
of 11